Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Assets: 2020-2025

Historic Assets for Janux Therapeutics (JANX) over the last 5 years, with Sep 2025 value amounting to $1.0 billion.

  • Janux Therapeutics' Assets rose 47.44% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 47.44%. This contributed to the annual value of $1.1 billion for FY2024, which is 179.05% up from last year.
  • As of Q3 2025, Janux Therapeutics' Assets stood at $1.0 billion, which was down 0.72% from $1.0 billion recorded in Q2 2025.
  • Janux Therapeutics' Assets' 5-year high stood at $1.1 billion during Q4 2024, with a 5-year trough of $341.5 million in Q2 2023.
  • In the last 3 years, Janux Therapeutics' Assets had a median value of $691.4 million in 2024 and averaged $700.6 million.
  • In the last 5 years, Janux Therapeutics' Assets surged by 2,242.13% in 2021 and then declined by 11.38% in 2023.
  • Janux Therapeutics' Assets (Quarterly) stood at $379.8 million in 2021, then decreased by 4.16% to $364.0 million in 2022, then increased by 4.50% to $380.4 million in 2023, then spiked by 179.05% to $1.1 billion in 2024, then surged by 47.44% to $1.0 billion in 2025.
  • Its Assets was $1.0 billion in Q3 2025, compared to $1.0 billion in Q2 2025 and $1.1 billion in Q1 2025.